LeMaitre Vascular (NASDAQ: LMAT) and Fulgent Genetic (NASDAQ:FLGT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.


LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.6%. Fulgent Genetic does not pay a dividend. LeMaitre Vascular pays out 31.9% of its earnings in the form of a dividend.

Institutional and Insider Ownership

66.3% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 16.8% of Fulgent Genetic shares are owned by institutional investors. 23.7% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares LeMaitre Vascular and Fulgent Genetic’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
LeMaitre Vascular $96.40 million 7.36 $23.12 million $0.69 54.03
Fulgent Genetic $20.81 million 3.44 $2.17 million ($0.38) -10.61

LeMaitre Vascular has higher revenue and earnings than Fulgent Genetic. Fulgent Genetic is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.


This table compares LeMaitre Vascular and Fulgent Genetic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LeMaitre Vascular 14.19% 15.02% 12.97%
Fulgent Genetic -0.42% -0.02% -0.02%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for LeMaitre Vascular and Fulgent Genetic, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LeMaitre Vascular 0 3 3 0 2.50
Fulgent Genetic 0 0 3 0 3.00

LeMaitre Vascular presently has a consensus target price of $30.50, indicating a potential downside of 18.19%. Fulgent Genetic has a consensus target price of $10.67, indicating a potential upside of 164.68%. Given Fulgent Genetic’s stronger consensus rating and higher possible upside, analysts clearly believe Fulgent Genetic is more favorable than LeMaitre Vascular.


LeMaitre Vascular beats Fulgent Genetic on 10 of the 13 factors compared between the two stocks.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.

Fulgent Genetic Company Profile

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.